Humacyte is trading 5.06% up at $0.43 on October 23, 2026, after positive interim V012 Phase 3 results presented at ASN Kidney Week. - In the first 80 patients, investigational ATEV met the primary endpoint, averaging 220 catheter-free days in year one versus 129 with an AV fistula. - Results also showed faster access to functional use; Humacyte plans to seek FDA label expansion for hemodialysis access. - The release reported no stock-market reaction or trading volume.